Nash, P., Coates, L., Kivitz, A., Mease, P., Gladman, D., Covarrubias-Cobos, J., . . . Kanik, K. (2018). Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: Data from the third interim analysis of opal balance, an open-label, long-term extension study. BMJ Publishing Group Limited.
Trích dẫn kiểu Chicago (xuất bản lần thứ 7)Nash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of Opal Balance, an Open-label, Long-term Extension Study. BMJ Publishing Group Limited, 2018.
Trích dẫn kiểu MLA (xuất bản lần thứ 9)Nash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of Opal Balance, an Open-label, Long-term Extension Study. BMJ Publishing Group Limited, 2018.